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BACKGROUND
• Stent thrombosis (ST) is a highly morbid complication of percutaneous coronary intervention (PCI), which manifests 
commonly as ST-segment elevation myocardial infarction (STEMI).1,2
• It has been reported in 3 - 4.4% of cases of STEMI in “real-world” contemporary population.3,4
• Treatment for stent thrombosis almost always requires emergent repeat PCI, although optimal reperfusion is only 
achieved in two thirds of patients. As a result, it has been associated with 30-day mortality rates of 10 % to 25% and 
≈ 20% of patients with a first stent thrombosis experience a recurrent stent thrombosis episode within 2 years.5
• To evaluate the prevalence of stent thrombosis among STEMI patients and its outcome.
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METHODS
• For each group we compared clinical features and adverse events. 
• Primary endpoint was the occurrence of cardiovascular death at 1 year; follow-up was completed in 96% of patients.
2531 patients  admitted 
with ACS from





confirmed stent thrombosis 
(n=27, 2.2%)
Group 2:









Age (years) 59 ± 11 62 ± 14 NS
Women (%) 14.8 19.1 NS
Cardiovascular Risk Factors
Hypertension (%) 48.1 57.2 NS
Diabetes (%) 37 22 NS
Dyslipidaemia (%) 63 49.8 NS
Smoking (%) 40.7 38.6 NS
Previous smoker (%) 23.1 16.7 NS
Previous Vascular Disease
Myocardial Infarction  (%) 92.6 7.8 <0.001
Angina  (%) 25.9 7.8 0.005
PTCA  (%) 100 4.6 <0.001
CABG  (%) 0.0 1.1 NS
Stroke  (%) 3.7 6.1 NS







Systolic pressure (mmHg) 125± 21 127± 21 NS
Heart rate (bpm) 79 77 NS
Killip classification > 2 (%) 7.4 4.1 NS
Cardiogenic shock (%) 11.1 5.9 NS
Anaemia (%) 3.7 22.4 0.017
Clearance creatinine
< 60 mL/min/1,73 m2 (%) 
14.8 17.6 NS
Blood Analysis
Haemoglobin (g/dl) 14.9 ± 1.8 13.9 ± 1.9 0.008
Platelets (x103) 453 ± 89 170 ± 58 0.014
Peak of troponin (ng/mL) 72. ± 84 92 ±119 NS
Left systolic dysfunction (%) 77.8 75.9 NS
Right systolic dysfunction (%) 7.4 6.3 NS








Time symptoms-reperfusion 3h:06’ 4h:29’ NS





Aspirin (%) 100 99.2 NS
Clopidogrel (%) 100 99.2 NS
ACE inhibitor (%) 88.9 86.5 NS
Beta blocker (%) 92.6 85.8 NS
Statins (%) 100 98.2 NS
Diuretics  (%) 22.2 33.6 NS
Inotropics (%) 14.8 9.6 NS
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multivessel disease 44,4% 
multisegment disease 7,3%
Stent thrombosis classification
Previous context of stent implantation ST-vessel and segment affected
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• Stent thrombosis accounts for 2.2% in our cohort of STEMI patients, being the majority treated with balloon angioplasty.
• The more frequent clinical presentation was acute and very late stent thrombosis, the last mainly due to 1st generation drug eluting stents.
• Stent thrombosis patients need more frequently triple antiplatelet therapy and suffer more malignant arrhythmias, post-infarction angor and  
reinfarction.
• Our patients with definite stent thrombosis did not have poorer in-hospital survival compared with those with native coronary disease, but they had 
higher cardiovascular death at one-year follow-up.
CONCLUSION
• 1-year cardiovascular mortality
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